Leerink Partnrs Has Positive Forecast for BNTC Q2 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC) – Investment analysts at Leerink Partnrs boosted their Q2 2026 earnings per share (EPS) estimates for Benitec Biopharma in a note issued to investors on Monday, November 17th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of ($0.19) per share for the quarter, up from their previous estimate of ($0.25). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.06) EPS and FY2027 earnings at ($1.04) EPS.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.13.

Other equities research analysts have also recently issued reports about the company. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 price objective (down from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. Zacks Research raised Benitec Biopharma from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Citigroup reissued an “outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, November 4th. Wall Street Zen cut shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, JMP Securities set a $22.00 price target on shares of Benitec Biopharma in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.83.

Benitec Biopharma Trading Down 3.2%

NASDAQ:BNTC opened at $13.10 on Thursday. The company’s 50 day moving average price is $14.43 and its 200-day moving average price is $13.73. The company has a quick ratio of 54.67, a current ratio of 54.67 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 52 week low of $9.49 and a 52 week high of $17.15. The stock has a market cap of $343.88 million, a price-to-earnings ratio of -8.91 and a beta of 0.23.

Hedge Funds Weigh In On Benitec Biopharma

Hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. grew its position in shares of Benitec Biopharma by 40.5% during the third quarter. Ameriprise Financial Inc. now owns 154,414 shares of the biotechnology company’s stock worth $2,166,000 after purchasing an additional 44,489 shares in the last quarter. UBS Group AG boosted its stake in Benitec Biopharma by 458.8% in the 3rd quarter. UBS Group AG now owns 99,941 shares of the biotechnology company’s stock worth $1,402,000 after purchasing an additional 82,057 shares during the period. BNP Paribas Financial Markets grew its holdings in Benitec Biopharma by 44.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 904 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Benitec Biopharma during the third quarter valued at approximately $79,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Benitec Biopharma by 2.4% in the third quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company’s stock worth $13,919,000 after buying an additional 22,948 shares in the last quarter. Institutional investors own 52.19% of the company’s stock.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L bought 1,481,481 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was bought at an average price of $13.50 per share, with a total value of $19,999,993.50. Following the acquisition, the director owned 9,538,175 shares of the company’s stock, valued at approximately $128,765,362.50. This represents a 18.39% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.80% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.